← Research
Sep 2014 Open-Label Trial
Pilot Study of the 5-HT2AR Agonist Psilocybin in the Treatment of Tobacco Addiction
Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR — Johns Hopkins University School of Medicine
Published in Journal of Psychopharmacology
An open-label pilot in 15 smokers combining psilocybin sessions with cognitive behavioral therapy for smoking cessation. 12 of 15 (80%) were biologically verified abstinent at 6-month follow-up — a notably high rate for any smoking-cessation intervention, though the open-label design means it can't isolate psilocybin's specific contribution.
Read the Full Paper at Journal of Psychopharmacology